Eisai Co., Ltd. (TYO:4523)
Japan
· Delayed Price · Currency is JPY 4,668.00
-41.00 (-0.87%)
At close: Dec 5, 2025
Eisai Employees
Eisai had 10,917 employees as of March 31, 2025. The number of employees decreased by 150 or -1.36% compared to the previous year.
Employees
10,917
Change (1Y)
-150
Growth (1Y)
-1.36%
Revenue / Employee
73.68M JPY
Profits / Employee
4.52M JPY
Market Cap
1,315.87B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Chugai Pharmaceutical | 5,026 |
| HOYA Corporation | 37,909 |
| Takeda Pharmaceutical Company | 47,455 |
| Daiichi Sankyo Company | 19,765 |
| Otsuka Holdings | 35,338 |
| Astellas Pharma | 13,643 |
| Shionogi & | 4,955 |
| Olympus | 29,297 |
Eisai News
- 2 days ago - Eisai And Biogen Report Long-Term Benefits Of LEQEMBI In Early Alzheimer's Disease - Nasdaq
- 2 days ago - Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 - PRNewsWire
- 4 days ago - Eisai : Etalanetug Demonstrates Reduction Of EMTBR-tau243 In Phase Ib/II Alzheimer's Study - Nasdaq
- 4 days ago - Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 - PRNewsWire
- 8 days ago - Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot - Benzinga
- 8 days ago - Eisai Announces Filing Of New Drug Application For Leqembi In Japan - Nasdaq
- 11 days ago - Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - Benzinga
- 18 days ago - Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - PRNewsWire